Biosimulation Market Size, Share, Opportunities, And Trends By Type (Software, Services), By Application (Drug Development, Drug Discovery, Others), By End-User Industry (Pharmaceutical Companies, Academic Institutions, Research Organizations, Others), And By Geography - Forecasts From 2025 To 2030

The biosimulation market is predicted to accelerate at a CAGR of 14.91% to be worth US$8.33 billion by 2030 from US$4.16 billion by 2025.

Biosimulation refers to a computer-aided program that simulates biological processes and systems. It is being used extensively for pharmaceutical drug development to mimic the flow of diseases and then run the designed medicine through the simulation to observe its impact on the disease and the body. The increase in investment in R&D has been a major reason for the growth in the biosimulation market.

The pharmaceutical companies segment will account for a significant market share and is anticipated to grow at a substantial rate in the coming years. This is due to the increasing adoption of in silico models for developing new drugs in areas such as cancer, diabetes, and central nervous system diseases. Companies are investing heavily in R&D activities to prolong the lifecycles of patent-expiring drugs by incorporating a biosimulation approach to develop drug variants. For instance, Rhenovia Pharma Ltd., a biotech company, utilized in silico models to identify better treatment approaches related to bipolar disorders, depression, schizophrenia, and Alzheimer’s disease.

Market Restraints:

There is a lack of standardization in biosimulation. Biosimulation uses a variety of models, tools, and languages for processing and capturing many different aspects of biological processes. The bodies governing it are yet to standardize the use of biosimulation technologies in the process of drug development and discovery.

North America will witness significant growth. 

The North American region will witness significant growth in the market of biosimulation. The growth in the biotechnology and pharmaceutical industry, increase in R&D investment by these pharmaceutical and biotechnology companies, and increase in the use of personalized medicines are some of the major factors driving the market growth. Moreover, the U.S. Food and Drug Administration (FDA) firmly recommends simulation processes in drug development and discovery, thereby boosting growth in the region.

Market Developments:

• In October 2024, Simulations Plus, Inc. received FDA approval for a grant in collaboration with the University of Strathclyde and InnoGI Technologies, focusing on advancing biosimulation applications. 
• In July 2024, Certara announced the acquisition of Chemaxon, a cheminformatics software provider, to enhance its drug discovery software portfolio, reflecting continued growth in biosimulation tools. 

The rise in demand for the biosimulation market has compelled major players such as Certara and Simulations Plus to focus on enhancing their global presence by adopting inorganic growth strategies.

The global Biosimulation Market report delivers a thorough analysis of the industry landscape, offering strategic and executive-level insights supported by data-driven forecasts and detailed analysis. This regularly updated report provides decision-makers with actionable intelligence on current market trends, emerging opportunities, and competitive dynamics. It assesses demand across key market segments, categorized by type into Software and Services, while exploring their distinct roles in the biosimulation ecosystem. The report further evaluates applications driving the market, including Drug Development, Drug Discovery, and other emerging uses.

Biosimulation Market Segmentations:

Biosimulation Market Segmentation by type

The market is analyzed by type into the following:

• Software
• Services

Biosimulation Market Segmentation by application

The report analyzes the market by application as below:

• Drug Development
• Drug Discovery
• Others

Biosimulation Market Segmentation by end-user

The report analyzes the market by end-user as below:

• Pharmaceutical Companies
• Academic Institutions
• Research Organizations
• Others

Biosimulation Market Segmentation by regions:

The study also analysed the Biosimulation Market into the following regions, with country level forecasts and analysis as below:

• North America (US, Canada and Mexico)
• South America (Brazil, Argentina, and Others)
• Europe (Germany, UK, France, Spain and Others
• Middle East and Africa (Saudi Arabia, UAE and Others)
• Asia Pacific (China, Japan, India, South Korea, Thailand, Indonesia, and Others)

Biosimulation Market Competitive Landscape:

The global Biosimulation Market features key players such as Rhenovia Pharma, Accelrys, Certara, Genedata, Leadscope, Compugen, Archimedes, Simulations Plus Inc., Schrodinger Inc. , Insilico Biotechnology, among others. 

Biosimulation Market Report Coverage:

This report provides extensive coverage as explained in the points below:

• Market size, forecasts, and trends by different types, with historical revenue data and analysis focusing on key factors driving adoption, current challenges faced by key players, and major growth areas.
• Market size, forecasts, and trends by application, with historical revenue data and analysis.
• Market size, forecasts, and trends by end-user, with historical revenue data and analysis across various segments.
• Biosimulation Market is also analysed across different regions, with historical data, regional share, attractiveness and opportunity of these solutions in different countries. The growth prospects and key players operating in these markets. The section also dwells on the macro factors, economic scenario and other complementing factors aiding in market growth. 
• Market dynamics: The section details the market growth factors, restraints, and opportunities in the market. The segment also presents complete market scenario with the help of Porter’s five forces model. 
• Competitive Intelligence: A thorough investigation on the competitive structure of the market presented through proprietary vendor matrix model, market share analysis of key players, insights on strategies of key players and recent major developments undertaken by the companies to gain competitive edge. 
• Research methodology: The assumptions and sources which were considered to arrive at the final market estimates. Additionally, how our model is refined to ensure most significant factors are taken into consideration with the proper hypothesis and bottom-up and top-down approaches enhance the reliability of forecasts further strengthening the trustworthiness of the numbers being presented. 

How this report is helpful to you and reasons for purchase?

• The report provides a strategic outlook of the Biosimulation Market to the decision-makers, analysts and other stakeholders in the easy to read format for taking informed decisions.
• The charts, tables and figures make it easy for the executives to gain valuable insights while skimming the report. 
• Analyst support through calls and email for timely clarification and incorporating additional requests. 
• Option of presentation or doc format with the estimates file to take care of diverse requirements. 
• 15% FREE customization with all our reports help cater additional requirements with significant cost-savings. 
• Option of purchasing specific segments of the study, including opting for summary reports or just the estimates file. 

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. BIOSIMULATION MARKET BY TYPE

5.1. Introduction

5.2. Software

5.3. Services

6. BIOSIMULATION MARKET BY APPLICATION

6.1. Introduction

6.2. Drug Development

6.3. Drug Discovery

6.4. Others

7. BIOSIMULATION MARKET BY END-USER

7.1. Introduction

7.2. Pharmaceutical Companies

7.3. Academic Institutions

7.4. Research Organizations

7.5. Others

8. BIOSIMULATION MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Italy

8.4.5. Spain

8.4.6. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. India

8.6.4. South Korea

8.6.5. Taiwan

8.6.6. Thailand

8.6.7. Indosneisa

8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Rhenovia Pharma

10.2. Certara

10.3. Genedata

10.4. Leadscope

10.5. Simulations Plus Inc.

10.6. Schrodinger Inc. 

10.7. Insilico Biotechnology.

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

LIST OF FIGURES

LIST OF TABLES

Rhenovia Pharma

Certara

Genedata

Leadscope

Simulations Plus Inc.

Schrödinger Inc. 

Insilico Biotechnology